XHKG
1302
Market cap1.16bUSD
Aug 08, Last price
2.07HKD
1D
-5.05%
1Q
31.85%
Jan 2017
11.29%
IPO
728.00%
Name
LifeTech Scientific Corp
Chart & Performance
Profile
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The company operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac Pacing and Electrophysiology Business segments. Its products include LAmbre left atrial appendage closure systems, as well as CeraFlex, Cera, Heart, and Konara-MF VSD occluders; Ankura thoracic aortic aneurysm and abdominal aortic aneurysm stent graft systems; delivery systems, such as Fustar steerable and SteerEase introducers; Aegisy vena cava filters; Cera vascular plug systems; AcuMark sizing balloons; LawMax dilators; and SeQure snare systems, as well as pacemakers. The company is also involved in the biomedical research and development; manufacturing and trading of materials for hemp; staff training and internal personnel management business; information consulting for investors; and manufacturing and trading of medical devices, as well as technical, consulting, and technology services. It has operations in Mainland China, India, rest of Asia, Europe, South America, Africa, and internationally. LifeTech Scientific Corporation was founded in 1999 and is headquartered in Shenzhen, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | 1,303,699 2.88% | 1,267,175 15.48% | 1,097,310 18.59% | |||||||
Cost of revenue | 1,129,381 | 984,049 | 779,563 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 174,318 | 283,126 | 317,747 | |||||||
NOPBT Margin | 13.37% | 22.34% | 28.96% | |||||||
Operating Taxes | 30,504 | 68,091 | 59,307 | |||||||
Tax Rate | 17.50% | 24.05% | 18.66% | |||||||
NOPAT | 143,814 | 215,035 | 258,440 | |||||||
Net income | 222,388 -15.52% | 263,242 -19.09% | 325,337 11.24% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | (20,762) | (471,179) | ||||||||
BB yield | 0.20% | 4.15% | ||||||||
Debt | ||||||||||
Debt current | 3,787 | 6,293 | 5,037 | |||||||
Long-term debt | 6,171 | 12,299 | 14,311 | |||||||
Deferred revenue | 37,174 | |||||||||
Other long-term liabilities | 608,119 | 599,255 | 142,500 | |||||||
Net debt | (1,593,870) | (1,692,433) | (1,539,939) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 418,049 | 388,318 | ||||||||
CAPEX | (200,831) | (335,473) | ||||||||
Cash from investing activities | (453,882) | (458,468) | ||||||||
Cash from financing activities | 182,709 | (215,201) | ||||||||
FCF | 59,375 | (201,431) | 274,946 | |||||||
Balance | ||||||||||
Cash | 1,181,888 | 1,179,312 | 833,792 | |||||||
Long term investments | 421,940 | 531,713 | 725,495 | |||||||
Excess cash | 1,538,643 | 1,647,666 | 1,504,422 | |||||||
Stockholders' equity | 3,475,429 | 1,606,008 | 1,459,857 | |||||||
Invested Capital | 2,549,884 | 2,326,513 | 1,605,011 | |||||||
ROIC | 5.90% | 10.94% | 16.39% | |||||||
ROCE | 4.26% | 7.20% | 10.37% | |||||||
EV | ||||||||||
Common stock shares outstanding | 4,394,487 | 4,446,121 | 4,405,420 | |||||||
Price | 1.39 -40.85% | 2.35 -8.91% | 2.58 -29.51% | |||||||
Market cap | 6,108,337 -41.54% | 10,448,384 -8.07% | 11,365,984 -31.94% | |||||||
EV | 4,495,389 | 8,709,679 | 10,013,536 | |||||||
EBITDA | 174,318 | 360,285 | 384,853 | |||||||
EV/EBITDA | 25.79 | 24.17 | 26.02 | |||||||
Interest | 722 | 632 | ||||||||
Interest/NOPBT | 0.26% | 0.20% |